Alchemedicine Inc. has prepared and tested new angiotensin AT1 receptor (AGTR1) antagonists reported to be useful for the treatment of cancer, hypertension, glaucoma and renal disorders.

Research at Seoul National University has led to the identification of thiourea compounds acting as nuclear receptor RORα (RORA) agonists reported to be useful for the treatment of inflammation and metabolic diseases.

An Agios Pharmaceuticals Inc. patent describes branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) inhibitors reported to be useful for the treatment of isovaleric acidemia, maple syrup urine disease, methylmalonic acidemia and propionic acidemia.

Case Western Reserve University has patented conjugates consisting of a PSMA-targeting moiety covalently linked to a chelating agent comprising metals.

Researchers at West China Hospital, Sichuan University have identified remimazolam derivatives reported to be useful for the treatment of sedation and as anesthetics.

Insilico Medicine Inc. has reported the development of ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors described as useful for the treatment of cancer.

Sanofi SA has prepared and tested isoxazolidines acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. As such, they are reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and incontinentia pigmenti.

Research at Biomea Fusion Inc. has led to the development of GTPase KRAS (G12C mutant) and (G12D mutant) inhibitors potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Two Vigil Neuroscience Inc. patents describe triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson’s, Alzheimer’s and Nasu-Hakola diseases.

Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have jointly developed S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.